Risk factors

Oil and natural gas operations in Alberta and land investments and drilling in Hawaii drive Barnwell Industries' business risks.

Keysight Technologies faces significant global macroeconomic, geopolitical, and supply chain vulnerabilities impacting its international technology and electronics markets. Intellectual property litigation, particularly a patent infringement lawsuit filed by Centripetal Networks, poses material operational risks. Regulatory compliance, environmental commitments to net zero emissions, and tax complexities heavily influence ongoing business strategies.

Accumulated deficit reached $75.0 million with a going concern warning from auditors. Reliance on Zimmer for global distribution of strip and grid electrodes. Nasdaq minimum bid price compliance notice received in July 2024.

Company operates as an internally managed BDC exposed to private debt, gemstone asset-based lending, and interest rate volatility.

Compass Minerals faces severe operational concentration risks in underground mining, brine extraction at the Great Salt Lake, and weather-dependent deicing salt sales. Financial flexibility is constrained by $922.8 million of debt, internal control material weaknesses, and the elimination of cash dividends.

Substantially all revenue depends on intelligent mobile imaging technology and software products, heavily tied to check use. Acquisitions like ID R&D and HooYu create integration, financial, and operational risks. Customer concentration is high, with one customer providing 17 percent of total revenue.

Housing market cyclicality and raw material price volatility dominate our operational risks.

RCI Hospitality Holdings faces core risks from operating adult entertainment nightclubs and restaurants, including intense competition, strict regulation, and employment law exposures.

Upexi faces intense competition in the hemp-based and CBD product market against better-resourced rivals.

Veru's risk profile centers heavily on clinical trial execution and funding risks for enobosarm and sabizabulin. The company faces a going concern warning, Nasdaq delisting notice, and SEC Form S-3 ineligibility affecting capital raises.

Applied Materials relies on cyclical semiconductor and display equipment markets with high customer concentration in Asia.

Edesa Biotech faces significant operating losses with an accumulated deficit of $58.6 million and needs substantial additional capital to fund clinical trials. The company depends heavily on third parties for manufacturing monoclonal antibodies and conducting clinical trials for candidates like EB05, EB06, EB01, and EB07. Operations are concentrated around specific disease targets including vitiligo, chronic ACD, ARDS, and pulmonary fibrosis.